MAPT and Alzheimer disease: We used homogenates from the temporal cortex (Brodmann area 22) because in early stages of AD (Braak stages I-III) this area is largely free of neurofibrils, whereas in late AD stages (Braak stages V-VI) the temporal cortex is severely affected by tau pathology [28].